ArticleFrontiers in microbiology2022
Complete genome sequences of two
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Avian PathogenicVeterinary sciences · 2025Review
- Emergence, Molecular Characteristics and Resistance Mechanisms of Colistin-ResistantInfection and drug resistance · 2025Article
- A Systematic Review and Comprehensive Analysis ofAntibiotics (Basel, Switzerland) · 2024Review
- A Newly Incompatibility F Replicon Allele (FIB81) in Extensively Drug-ResistantInternational journal of molecular sciences · 2024Article
- Antimicrobial Resistance Surveillance: Data Harmonisation and Data Selection within Secondary Data Use.Antibiotics (Basel, Switzerland) · 2024Article
- Characterisation of colistin resistance in Gram-negative microbiota of pregnant women and neonates in Nigeria.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colistin is a last-resort antibiotic used in the treatment of multidrug resistant Gram-negative bacteria. However, the activity and efficacy of colistin has been compromised by the worldwide spread of the mobile colistin resistance genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.